AdaptHealth (NASDAQ:AHCO) Insider Russell Schuster III Sells 11,275 Shares

AdaptHealth Corp. (NASDAQ:AHCO) insider Russell Schuster III sold 11,275 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the transaction, the insider owned 136,538 shares in the company, valued at approximately $1,373,572.28. This represents a 7.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AdaptHealth Stock Up 0.8%

Shares of NASDAQ:AHCO opened at $9.73 on Thursday. AdaptHealth Corp. has a 1 year low of $8.06 and a 1 year high of $13.43. The company has a market cap of $1.32 billion, a PE ratio of -15.69, a P/E/G ratio of 0.55 and a beta of 1.47. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.92 and a quick ratio of 0.71. The stock’s 50-day moving average is $11.56 and its 200 day moving average is $10.55.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13). The business had revenue of $819.80 million for the quarter, compared to analysts’ expectations of $796.63 million. AdaptHealth had a negative net margin of 2.42% and a positive return on equity of 2.76%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) EPS. Sell-side analysts anticipate that AdaptHealth Corp. will post 0.63 EPS for the current year.

Institutional Trading of AdaptHealth

A number of hedge funds have recently made changes to their positions in AHCO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of AdaptHealth by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock worth $656,000 after purchasing an additional 2,564 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of AdaptHealth by 32.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock worth $6,192,000 after purchasing an additional 139,828 shares in the last quarter. Woodline Partners LP bought a new stake in shares of AdaptHealth in the 1st quarter worth approximately $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of AdaptHealth by 18.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock worth $2,534,000 after acquiring an additional 35,879 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of AdaptHealth by 1.3% in the second quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company’s stock worth $1,997,000 after acquiring an additional 2,718 shares during the last quarter. 82.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on AHCO shares. Jefferies Financial Group restated a “hold” rating and set a $11.00 target price on shares of AdaptHealth in a report on Monday, April 20th. Leerink Partners decreased their target price on AdaptHealth from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Royal Bank Of Canada upped their target price on AdaptHealth from $13.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Robert W. Baird set a $18.00 price target on AdaptHealth in a research note on Wednesday, May 6th. Finally, Truist Financial upped their price target on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.29.

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.